血浆miR-128在胶质母细胞瘤诊断中的作用研究

Role of plasma miR-128 in diagnosis and treatment of glioblastoma

目的探讨血浆中miR-128在胶质母细胞瘤诊断的作用。方法收集30例不同级别胶质瘤病人的肿瘤组织和血浆标本作为实验组,同时收集健康成年人的脑组织和血浆作为正常对照组。利用实时定量PCR,检测组织和血浆中miR-128的表达水平。结果 miR-128在各级胶质母细胞瘤组织中的表达较正常对照组均明显降低(均P<0.005),且与肿瘤的病理级别呈负相关(r=-0.497,P<0.001)。miR-128在胶质母细胞瘤病人血浆中的表达明显低于正常对照组(P<0.001)。血浆miR-128诊断胶质母细胞瘤的特异性和敏感性分别为90%和100%。结论 miR-128可作为胶质母细胞瘤的一种新型血浆标记物,用于指导诊断。

Objective To explore the role of plasma miR-128 in glioblastoma. Methods The samples of tumor tissue and plasma were collected from 30 patients with different grade glioblastoma as experimental group. The samples of brain tissue and plasma were collected from 10 healthy adults as normal control group. The expressions of miR-128 in tissue and plasma were tested by real-time quantitative polymerase chain reaction （RT-PCR）. Results The expressions of miR-128 in tissue of glioblastoma patients in experimental group were lower than those in normal control group （all P 〈 0.005）. The expression of miR-128 in tissue of glioblastoma was negatively related to the pathological grade of tumor （r = -0.479, P 〈 0.001）. The expressions of miR-128 in plasma of glioblastoma patients in experimental group were lower than those in normal control group （P 〈 0.001）. The specificity and sensitivity of plasma miR-128 in the diagnosis of glioblastoma were 90% and 100%. Conclusion The plasma miR-128 can be used as a novel biomarker of glioblastoma, which can guide the treatment.